Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of Iparomlimab (QL1604) in Advanced Solid Tumors
NCT05801094Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab in solid tumor, Cervical Cancer (CC) and hepatocellular carcinoma (HCC), sponsored by Qilu Pharmaceutical. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
iparomlimab
03
Conditions
solid tumorCervical Cancer (CC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05801094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801094.